Hubbry Logo
PlateletPlateletMain
Open search
Platelet
Community hub
Platelet
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Platelet
Platelet
Platelet
View on Wikipedia
from Wikipedia
Platelets
Image from a light microscope (500 ×) from a Giemsa-stained peripheral blood smear showing platelets (small purple dots) surrounded by red blood cells (large gray circular structures)
Details
PrecursorMegakaryocytes
FunctionFormation of blood clots; prevention of bleeding
Identifiers
Latinthrombocytus
MeSHD001792
FMA62851
Anatomical terms of microanatomy

Platelets or thrombocytes (from Ancient Greek θρόμβος (thrómbos) 'clot' and κύτος (kútos) 'cell') are a part of blood whose function (along with the coagulation factors) is to react to bleeding from blood vessel injury by clumping to form a blood clot.[1] Platelets have no cell nucleus; they are fragments of cytoplasm from megakaryocytes which reside in bone marrow or lung tissue,[2] and then enter the circulation. Platelets are found only in mammals, whereas in other vertebrates (e.g. birds, amphibians), thrombocytes circulate as intact mononuclear cells.[3]: 3 

The ligands, denoted by letter L, signal for platelets (P) to migrate towards the wound (Site A). As more platelets gather around the opening, they produce more ligands to amplify the response. The platelets congregate around the wound in order to create a cap to stop blood flow out of the tissue.

One major function of platelets is to contribute to hemostasis: the process of stopping bleeding at the site where the lining of vessels (endothelium) has been interrupted. Platelets gather at the site and, unless the interruption is physically too large, they plug it. First, platelets attach to substances outside the interrupted endothelium: adhesion. Second, they change shape, turn on receptors and secrete chemical messengers: activation. Third, they connect to each other through receptor bridges: aggregation.[4] Formation of this platelet plug (primary hemostasis) is associated with activation of the coagulation cascade, with resultant fibrin deposition and linking (secondary hemostasis). These processes may overlap: the spectrum is from a predominantly platelet plug, or "white clot" to a predominantly fibrin, or "red clot" or the more typical mixture. Berridge adds retraction and platelet inhibition as fourth and fifth steps,[5] while others would add a sixth step, wound repair.[6] Platelets participate in both innate[7] and adaptive[8] intravascular immune responses.

In addition to facilitating the clotting process, platelets contain cytokines and growth factors which can promote wound healing and regeneration of damaged tissues.[9][10]

Term

[edit]

The term thrombocyte (clot cell) came into use in the early 1900s and is sometimes used as a synonym for platelet; but not generally in the scientific literature, except as a root word for other terms related to platelets (e.g. thrombocytopenia meaning low platelets).[3]: v3  The term thrombocytes are proper for mononuclear cells found in the blood of non-mammalian vertebrates: they are the functional equivalent of platelets, but circulate as intact cells rather than cytoplasmic fragments of bone marrow megakaryocytes.[3]: 3 

In some contexts, the word thrombus is used interchangeably with the word clot, regardless of its composition (white, red, or mixed). In other contexts it is used to contrast a normal from an abnormal clot: thrombus arises from physiologic hemostasis, thrombosis arises from a pathologic and excessive quantity of clot.[11] In a third context it is used to contrast the result from the process: thrombus is the result, thrombosis is the process.

Structure

[edit]

Structurally the platelet can be divided into four zones, from peripheral to innermost:[12]

Shape

[edit]

Circulating inactivated platelets are biconvex discoid (lens-shaped) structures,[13][3]: 117–118  2–3 μm in greatest diameter.[14] Activated platelets have cell membrane projections covering their surface.

In a first approximation, the shape can be considered similar to oblate spheroids, with a semiaxis ratio of 2 to 8.[15] This approximation can be used to model the hydrodynamic and optical properties of a population, as well as to restore the geometric parameters of individual measured platelets by flow cytometry.[16] More accurate biophysical models of platelet surface morphology that model its shape from first principles, make it possible to obtain a more realistic platelet geometry in a calm and activated state.[17]

Development

[edit]
Platelets derive from multipotent marrow stem cells.
  • Megakaryocyte and platelet production is regulated by thrombopoietin, a hormone produced in the kidneys and liver.
  • Each megakaryocyte produces between 1,000 and 3,000 platelets during its lifetime.
  • An average of 1011 platelets are produced daily in a healthy adult.
  • Reserve platelets are stored in the spleen and are released when needed by splenic contraction induced by the sympathetic nervous system.
Platelets extruded from megakaryocytes
  • The average life span of circulating platelets is 8 to 9 days.[18] Life span of individual platelets is controlled by the internal apoptotic regulating pathway, which has a Bcl-xL timer.[19]
  • Old platelets are destroyed by phagocytosis in the spleen and liver.

Hemostasis

[edit]
Main article: Hemostasis
3D rendering of four inactivated and three activated platelets

The fundamental function of platelets is to clump together to stop acute bleeding. This process is complex, as more than 193 proteins and 301 interactions are involved in platelet dynamics.[4] Despite much overlap, platelet function can be modeled in three steps:

Adhesion

[edit]

Thrombus formation on an intact endothelium is prevented by nitric oxide,[20] prostacyclin,[21] and CD39.[22]

Endothelial cells attach to the subendothelial collagen by von Willebrand factor (VWF), which these cells produce. VWF is also stored in the Weibel-Palade bodies of the endothelial cells and secreted constitutively into the blood. Platelets store vWF in their alpha granules.

When the endothelial layer is disrupted, collagen and VWF anchor platelets to the subendothelium. Platelet GP1b-IX-V receptor binds with VWF; and GPVI receptor and integrin α2β1 bind with collagen.[23]

Activation

[edit]
Scanning electron micrograph of blood cells. From left to right: human erythrocyte, activated platelet, leukocyte.

Inhibition

[edit]

Factors from the lining of vessels stop platelets from activating. An intact endothelial lining inhibits platelet activation by producing nitric oxide, endothelial-ADPase, and PGI2 (prostacyclin). Endothelial-ADPase degrades the platelet activator ADP.[24]

Resting platelets maintain active calcium efflux via a cyclic AMP-activated calcium pump. Intracellular calcium concentration determines platelet activation status, as it is the second messenger that drives platelet conformational change and degranulation. Endothelial prostacyclin binds to prostanoid receptors on the surface of resting platelets. This event stimulates the coupled Gs protein to increase adenylate cyclase activity and increases the production of cAMP, further promoting the efflux of calcium and reducing intracellular calcium availability for platelet activation.[25]

ADP binds to purinergic receptors on the platelet surface. Since the thrombocytic purinergic receptor P2Y12 is coupled to Gi proteins, ADP reduces platelet adenylate cyclase activity and cAMP production, leading to accumulation of calcium inside the platelet by inactivating the cAMP calcium efflux pump. The other ADP-receptor P2Y1 couples to Gq that activates phospholipase C-beta 2 (PLCB2), resulting in inositol 1,4,5-trisphosphate (IP3) generation and intracellular release of more calcium. This together induces platelet activation. Endothelial ADPase degrades ADP and prevents this from happening. Clopidogrel and related antiplatelet medications also work as purinergic receptor P2Y12 antagonists.[26] Data suggest that ADP activates the PI3K/Akt pathway during a first wave of aggregation, leading to thrombin generation and PAR‐1 activation, which evokes a second wave of aggregation.[27]

Trigger (induction)

[edit]

Platelet activation begins seconds after adhesion occurs. It is triggered when collagen from the subendothelium binds with its receptors (GPVI receptor and integrin α2β1) on the platelet. GPVI is associated with the Fc receptor gamma chain and leads via the activation of a tyrosine kinase cascade finally to the activation of PLC-gamma2 (PLCG2) and more calcium release.[28]

Tissue factor also binds to factor VII in the blood, which initiates the extrinsic coagulation cascade to increase thrombin production. Thrombin is a potent platelet activator, acting through Gq and G12. These are G protein-coupled receptors and they turn on calcium-mediated signaling pathways within the platelet, overcoming the baseline calcium efflux. Families of three G proteins (Gq, Gi, G12) operate together for full activation. Thrombin also promotes secondary fibrin-reinforcement of the platelet plug. Platelet activation in turn degranulates and releases factor V and fibrinogen, potentiating the coagulation cascade. Platelet plugging and coagulation occur simultaneously, with each inducing the other to form the final fibrin-crosslinked thrombus.[29][30]

Components (consequences)

[edit]
GPIIb/IIIa activation
[edit]

Collagen-mediated GPVI signalling increases the platelet production of thromboxane A2 (TXA2) and decreases the production of prostacyclin. This occurs by altering the metabolic flux of platelet's eicosanoid synthesis pathway, which involves enzymes phospholipase A2, cyclo-oxygenase 1, and thromboxane-A synthase. Platelets secrete thromboxane A2, which acts on the platelet's own thromboxane receptors on the platelet surface (hence the so-called "out-in" mechanism), and those of other platelets. These receptors trigger intraplatelet signaling, which converts GPIIb/IIIa receptors to their active form to initiate aggregation.[4]

Granule secretion
[edit]
Diagram of the structure of a platelet showing the granules

Platelets contain dense granules, lambda granules, and alpha granules. Activated platelets secrete the contents of these granules through their canalicular systems to the exterior. Bound and activated platelets degranulate to release platelet chemotactic agents to attract more platelets to the site of endothelial injury. Granule characteristics:

Morphology change
[edit]

As shown by flow cytometry and electron microscopy, the most sensitive sign of activation, when exposed to platelets using ADP, are morphological changes.[31] Mitochondrial hyperpolarization is a key event in initiating morphology changes.[32] Intraplatelet calcium concentration increases, stimulating the interplay between the microtubule/actin filament complex. The continuous changes in shape from the unactivated to the fully activated platelet are best seen via scanning electron microscopy. The three steps along this path are named early dendritic, early spread, and spread. The surface of the unactivated platelet looks similar to the surface of the brain–a wrinkled appearance from numerous shallow folds that increase the surface area; early dendritic, an octopus with multiple arms and legs; early spread, an uncooked frying egg in a pan, the "yolk" is the central body; and the spread, a cooked fried egg with a denser central body.

These changes are all brought about by the interaction of the microtubule/actin complex with the platelet cell membrane and open canalicular system (OCS), which is an extension and invagination of that membrane. This complex runs just beneath these membranes and is the chemical motor that pulls the invaginated OCS out of the interior of the platelet, like turning pants pockets inside out, creating the dendrites. This process is similar to the mechanism of contraction in a muscle cell.[33] The entire OCS thus becomes indistinguishable from the initial platelet membrane as it forms the "fried egg". This dramatic increase in surface area comes about with neither stretching nor adding phospholipids to the platelet membrane.[34]

Platelet-coagulation factor interactions: coagulation facilitation
[edit]

Platelet activation causes its membrane surface to become negatively charged. One of the signaling pathways turns on scramblase, which moves negatively charged phospholipids from the inner to the outer platelet membrane surface. These phospholipids then bind the tenase and prothrombinase complexes, two of the sites of interplay between platelets and the coagulation cascade. Calcium ions are essential for the binding of these coagulation factors.

In addition to interacting with vWF and fibrin, platelets interact with thrombin, Factors X, Va, VIIa, XI, IX, and prothrombin to complete formation via the coagulation cascade.[35][36] Human platelets do not express tissue factor.[35] Rat platelets do express tissue factor protein and carry both tissue factor pre-mRNA and mature mRNA.[37]

Aggregation

[edit]
Platelet clumps in a blood smear

Platelet aggregation begins minutes after activation, and occurs as a result of turning on the GPIIb/IIIa receptor, allowing these receptors to bind with vWF or fibrinogen.[4] Each platelet has around 60,000 of these receptors.[38] When any one or more of at least nine different platelet surface receptors are turned on during activation, intraplatelet signaling pathways cause existing GpIIb/IIIa receptors to change shape — curled to straight — and thus become capable of binding.[4]

Since fibrinogen is a rod-like protein with nodules on either end capable of binding GPIIb/IIIa, activated platelets with exposed GPIIb/IIIa can bind fibrinogen to aggregate. GPIIb/IIIa may also further anchor the platelets to subendothelial vWF for additional structural stabilisation.

Classically it was thought that this was the only mechanism involved in aggregation, but three other mechanisms have been identified which can initiate aggregation, depending on the velocity of blood flow (i.e. shear range).[39]

Immune function

[edit]

Platelets have a central role in innate immunity, initiating and participating in multiple inflammatory processes, directly binding and even destroying pathogens. Clinical data show that many patients with serious bacterial or viral infections have thrombocytopenia, thus reducing their contribution to inflammation. Platelet-leukocyte aggregates (PLAs) found in circulation are typical in sepsis or inflammatory bowel disease, showing the connection between thrombocytes and immune cells.[40]

The platelet cell membrane has receptors for collagen. Following rupture of the blood vessel wall, platelets are exposed and adhere to the collagen in the surrounding tissue.

Immunothrombosis

[edit]

As hemostasis is a basic function of thrombocytes in mammals, it also has its uses in possible infection confinement.[7] In case of injury, platelets, together with the coagulation cascade, provide the first line of defense by forming a blood clot. Hemostasis and host defense were thus intertwined in evolution. For example, in the Atlantic horseshoe crab (estimated to be over 400 million years old), the only blood cell type, the amebocyte, facilitates both the hemostatic function and immune functions, including encapsulation, phagocytosis of pathogens, and exocytosis of intracellular granules containing bactericidal defense molecules. Blood clotting supports immune function by trapping the bacteria.[41]

Thrombosis (blood coagulation in intact blood vessels) is usually viewed as a pathological immune response, leading to obturation of lumen of blood vessel and subsequent hypoxic tissue damage. In some cases, however, directed thrombosis (or immunothrombosis) can locally control the spread of an infection. The thrombosis is directed in concordance with platelets, neutrophils and monocytes. The process is initiated either by immune cells by activating their pattern recognition receptors (PRRs), or by platelet-bacterial binding. Platelets can bind to bacteria either directly through thrombocytic PRRs[40] and bacterial surface proteins, or via plasma proteins that bind both to platelets and bacteria.[42] Monocytes respond to bacterial pathogen-associated molecular patterns (PAMPs), or damage-associated molecular patterns (DAMPs) by activating the extrinsic pathway of coagulation. Neutrophils facilitate the blood coagulation by NETosis, while platelets facilitate neutrophils' NETosis. NETs bind tissue factor, binding the coagulation centers to the location of infection. They also activate the intrinsic coagulation pathway by providing a negatively charged surface for factor XII. Other neutrophil secretions, such as proteolytic enzymes which cleave coagulation inhibitors, also bolster the process.[7]

In case of imbalance in the regulation of immunothrombosis, this process can become aberrant. Regulatory defects in immunothrombosis are suspected to be a major factor in pathological thrombosis in forms such as disseminated intravascular coagulation (DIC) or deep vein thrombosis. DIC in sepsis is a prime example of both the dysregulated coagulation process and an undue systemic inflammatory response. It results in a multitude of microthrombi. These are similar in composition to the thrombi produced in native immunothrombosis — they are made up of fibrin, platelets, neutrophils and NETs.[7]

Inflammation

[edit]

Platelets rapidly deploy to sites of injury or infection. There, they are thought to modulate inflammatory processes via interactions with leukocytes and secretion of cytokines, chemokines, and other inflammatory mediators.[43][44][45][46][47] Platelets also secrete platelet-derived growth factor (PDGF).

Platelets modulate neutrophils by forming platelet-leukocyte aggregates (PLAs). These formations induce upregulated production of the complement receptor αmβ2 (Mac-1) integrin in neutrophils. Interaction with PLAs also induces degranulation and increased phagocytosis in neutrophils.

Platelets are the largest source of soluble CD40L (CD154) which induces production of reactive oxygen species (ROS) and upregulates expression of adhesion molecules (such as E-selectin, ICAM-1, and VCAM-1) in neutrophils. CD40L also activates macrophages and activates cytotoxic response in T and B lymphocytes.[40]

Mammalian platelets lacking nucleus are able to conduct autonomous locomotion.[48] Platelets are active scavengers, scaling walls of blood vessels and reorganising the thrombus. They are able to recognize and adhere to many surfaces, including bacteria, and can envelop them in their open canalicular system (OCP), leading to a proposal to name the process as covercytosis (OCS) rather than phagocytosis, as OCS is merely an invagination of outer plasma membrane. These platelet-bacteria bundles provide an interaction platform for neutrophils that destroy bacteria using NETs and phagocytosis.

Platelets also participate in chronic inflammatory disease, such as synovitis or rheumatoid arthritis.[49] Platelets are activated by collagen receptor glycoprotein IV (GPVI). Proinflammatory platelet microvesicles trigger constant cytokine secretion from neighboring fibroblast-like synoviocytes, most prominently Il-6 and Il-8. Inflammatory damage to the surrounding extracellular matrix continuously reveals more collagen, binding receptors on platelets and maintaining microvesicle production.

Adaptive immunity

[edit]

Activated platelets are able to participate in adaptive immunity, interacting with antibodies. They are able to specifically bind IgG through FcγRIIA, a receptor for IgG's constant fragment (Fc). When activated and bound to IgG-opsonised bacteria, platelets release reactive oxygen species (ROS), antimicrobial peptides, defensins, kinocidins and proteases, killing the bacteria directly.[50] Platelets also secrete proinflammatory and procoagulant mediators such as inorganic polyphosphates or platelet factor 4 (PF4), connecting innate and adaptive immune responses.[50][51]

Measurement and testing

[edit]

Measurement

[edit]

Platelet concentration in the blood (i.e. platelet count), can be measured manually using a hemocytometer, or by placing blood in an automated platelet analyzer using particle counting, such as a Coulter counter or optical methods.[52] Most common blood testing methods include platelet count in their measurements, usually reported as PLT.[53]

Platelet concentrations vary between individuals and over time, with the population average between 250,000 and 260,000 cells per mm3 (equivalent to per microliter), but the typical laboratory accepted normal range is between 150,000 and 400,000 cells per mm3 or 150–400 billion per liter.[53][52]

On for example optical densitometry, a first and second wave of platelet aggregation is seen, in this case for an ADP-initiated aggregation.

On a stained blood smear, platelets appear as dark purple spots, about 20% of the diameter of red blood cells. The smear reveals size, shape, qualitative number, and clumping. A healthy adult typically has 10 to 20 times more red blood cells than platelets.

Bleeding time

[edit]

Bleeding time was developed as a test of platelet function by Duke in 1910.[54] Duke's test measured the time taken for bleeding to stop from a standardized wound in the ear lobe that was blotted every 30 seconds, considering less than 3 minutes as normal.[55] Bleeding time has low sensitivity and specificity for mild to moderate platelet disorders and is no longer recommended for screening.[56]

Multiple electrode aggregometry

[edit]
Main article: Multiple electrode aggregometry

In multiple electrode aggregometry, anticoagulated whole blood is mixed with saline and a platelet agonist in a single-use cuvette with two pairs of electrodes. The increase in impedance between the electrodes as platelets aggregate onto them, is measured and visualized as a curve.[57][58]

Light transmission aggregometry

[edit]

In light transmission aggregometry (LTA), platelet-rich plasma is placed between a light source and a photocell. Unaggregated plasma allows relatively little light to pass through. After adding an agonist, the platelets aggregate, increasing light transmission, which is detected by a photocell.[59]

Whole blood impedance aggregometry

[edit]

Whole blood impedance aggregometry (WBA) measures the change in electrical impedance between two electrodes when platelet aggregation is induced by an agonist. Whole blood lumiaggregometry may increase the test sensitivity to impairment of platelet granule secretion.[60]

PFA-100

[edit]

The PFA-100 (Platelet Function Assay — 100) is a system for analysing platelet function in which citrated whole blood is aspirated through a disposable cartridge containing an aperture within a membrane coated with either collagen and epinephrine or collagen and ADP. These agonists induce platelet adhesion, activation and aggregation, leading to rapid occlusion of the aperture and cessation of blood flow termed the closure time (CT). An elevated CT with EPI and collagen can indicate intrinsic defects such as von Willebrand disease, uremia, or circulating platelet inhibitors. A follow-up test involving collagen and ADP is used to indicate if the abnormal CT with collagen and EPI was caused by the effects of acetyl sulfosalicylic acid (aspirin) or medications containing inhibitors.[61] The PFA-100 is highly sensitive to von Willebrand disease, but is only moderately sensitive to defects in platelet function.[62]

Clinical significance

[edit]

Spontaneous and excessive bleeding can occur because of platelet disorders. This bleeding can be caused by deficient numbers of platelets, dysfunctional platelets, or platelet densities over 1 million/microliter. (The excessive numbers create a relative von Willebrand factor deficiency due to sequestration.)[63][64]

Bleeding due to a platelet disorder or a coagulation factor disorder can be distinguished by the characteristics and location of the bleeding.[3]: 815, Table 39-4  Platelet bleeding involves bleeding from a cut that is prompt and excessive, but can be controlled by pressure; spontaneous bleeding into the skin which causes a purplish stain named by its size: petechiae, purpura, ecchymoses; bleeding into mucous membranes causing bleeding gums, nose bleed, and gastrointestinal bleeding; menorrhagia; and intraretinal and intracranial bleeding.

Excessive numbers of platelets, and/or normal platelets responding to abnormal vessel walls, can result in venous thrombosis and arterial thrombosis. The symptoms depend on the thrombosis site.

Disorders

[edit]

Platelet disorders can occur because there are not enough platelets, too many platelets, or the platelets do not function properly.[3]: vii 

Low platelet concentration is called thrombocytopenia, and is due to either decreased production, increased destruction of platelets, or platelets being sequestered in another part of the body. Elevated platelet concentration is called thrombocytosis, and is either congenital, reactive (to cytokines), or due to unregulated production: one of the myeloproliferative neoplasms or certain other myeloid neoplasms.

Normal platelets can respond to an abnormality on the vessel wall rather than to hemorrhage, resulting in inappropriate platelet adhesion/activation and thrombosis: the formation of a clot within an intact vessel. This type of thrombosis arises by mechanisms different from those of a normal clot: extending the fibrin of venous thrombosis; extending an unstable or ruptured arterial plaque, causing arterial thrombosis; and microcirculatory thrombosis. An arterial thrombus may partially obstruct blood flow, causing downstream ischemia, or may completely obstruct it, causing downstream tissue death.:[3]: vii 

Platelet aggregation function by disorders and agonists   edit
ADP Epinephrine Collagen Ristocetin
P2Y receptor defect[65] (including Clopidogrel) Decreased Normal Normal Normal
Adrenergic receptor defect[65] Normal Decreased Normal Normal
Collagen receptor defect[65] Normal Normal Decreased or absent Normal
Normal Normal Normal Decreased or absent
Decreased Decreased Decreased Normal or decreased
Storage pool deficiency[66] Absent second wave Partial
Aspirin or aspirin-like disorder Absent second wave Absent Normal

Thrombocytopenia

[edit]

Altered platelet function

[edit]

Thrombocytosis and thrombocythemia

[edit]

Pharmacology

[edit]

Anti-inflammatory drugs

[edit]

Some drugs used to treat inflammation have the unwanted side effect of suppressing normal platelet function. These are the non-steroidal anti-inflammatory drugs (NSAIDS). Aspirin irreversibly disrupts platelet function by inhibiting cyclooxygenase-1 (COX1), and hence normal hemostasis. The resulting platelets are unable to produce new cyclooxygenase because they have no DNA. Normal platelet function does not return until the use of aspirin has ceased and enough of the affected platelets have been replaced by new ones, which can take over a week. Ibuprofen, another NSAID, does not have such a long duration effect, with platelet function usually returning within 24 hours,[73] and taking ibuprofen before aspirin prevents the irreversible effects of aspirin.[74]

Drugs that suppress platelet function

[edit]

These drugs are used to prevent thrombus formation.

Oral agents

[edit]

Intravenous agents

[edit]

Drugs that stimulate platelet production

[edit]

Therapies

[edit]

Transfusion

[edit]
Main article: Platelet transfusion

Indications

[edit]

Platelet transfusion is most frequently used to correct unusually low platelet counts, either to prevent spontaneous bleeding (typically at counts below 10 billion/L) or in anticipation of medical procedures that necessarily involve some bleeding. For example, in patients undergoing surgery, a level below 50 billion/L is associated with abnormal surgical bleeding, and regional anaesthetic procedures such as epidurals are avoided for levels below 80 billion/L.[75] Platelets may also be transfused when the platelet count is normal but the platelets are dysfunctional, such as when an individual is taking aspirin or clopidogrel.[76] Finally, platelets may be transfused as part of a massive transfusion protocol, in which the three major blood components (red blood cells, plasma, and platelets) are transfused to address severe hemorrhage. Platelet transfusion is contraindicated in thrombotic thrombocytopenic purpura (TTP), as it fuels the coagulopathy. Platelet transfusion is generally ineffective, and thus contraindicated, for prophylaxis in immune thrombocytopenia (ITP), because the transfused platelets are immediately cleared; however, it is indicated to treat bleeding.[77]

Collection

[edit]
Platelet concentrate

Platelets are either isolated from collected units of whole blood and pooled to make a therapeutic dose, or collected by platelet apheresis: blood is taken from the donor, passed through a device which removes the platelets, and the remainder is returned to the donor in a closed loop. The industry standard is for platelets to be tested for bacteria before transfusion to avoid septic reactions, which can be fatal. Recently the AABB Industry Standards for Blood Banks and Transfusion Services (5.1.5.1) has allowed use of pathogen reduction technology as an alternative to bacterial screenings in platelets.[78]

Pooled whole-blood platelets, sometimes called "random" platelets, are separated by one of two methods.[79] In the US, a unit of whole blood is placed into a large centrifuge in what is referred to as a "soft spin". At these settings, the platelets remain suspended in the plasma. The platelet-rich plasma (PRP) is removed from the red cells, then centrifuged at a faster setting to harvest the platelets from the plasma. In other regions of the world, the unit of whole blood is centrifuged using settings that cause the platelets to become suspended in the "buffy coat" layer, which includes the platelets and the white blood cells. The "buffy coat" is isolated in a sterile bag, suspended in a small amount of red blood cells and plasma, then centrifuged again to separate the platelets and plasma from the red and white blood cells. Regardless of the initial method of preparation, multiple donations may be combined into one container using a sterile connection device to manufacture a single product with the desired therapeutic dose.

Apheresis platelets are collected using a mechanical device that draws blood from the donor and centrifuges the collected blood to separate out the platelets and other components to be collected. The remaining blood is returned to the donor. The advantage to this method is that a single donation provides at least one therapeutic dose, as opposed to the multiple donations for whole-blood platelets. This means that a recipient is exposed to fewer donors and has less risk of transfusion-transmitted disease and other complications. Sometimes a person such as a cancer patient who requires routine transfusions of platelets receives repeated donations from a specific donor to minimize risk. Pathogen reduction of platelets using for example, riboflavin and UV light treatments can reduce the infectious load of pathogens contained in donated blood products.[80][81] Another photochemical treatment process utilizing amotosalen and UVA light has been developed for the inactivation of viruses, bacteria, parasites, and leukocytes.[82] In addition, apheresis platelets tend to contain fewer contaminating red blood cells because the collection method is more efficient than "soft spin" centrifugation.

Storage

[edit]

Platelets collected by either method have a typical shelf life of five days. This results in supply shortages, as testing donations often requires up to a full day. No effective preservative solutions have been devised for platelets.

Platelets are stored under constant agitation at 20–24 °C (68–75 °F). Units cannot be refrigerated as this causes platelets to change shape and lose function. Storage at room temperature provides an environment where any introduced bacteria may proliferate and subsequently cause bacteremia. The United States requires products to be tested for the presence of bacterial contamination before transfusion.[83]

Platelets collected by using apheresis at an American Red Cross donation center

Delivery

[edit]

Platelets do not need to belong to the same A-B-O blood group as the recipient or be cross-matched to ensure immune compatibility between donor and recipient unless they contain a significant amount of red blood cells (RBCs). The presence of RBCs imparts a reddish-orange color to the product and is usually associated with whole-blood platelets. Some sites may type platelets, but this is not critical.

Prior to issuing platelets to the recipient, they may be irradiated to prevent transfusion-associated graft versus host disease or they may be washed to remove the plasma.

The change in the recipient's platelet count after transfusion is termed the "increment" and is calculated by subtracting the pre-transfusion platelet count from the post-transfusion count. Many factors affect the increment including body size, the number of platelets transfused, and clinical features that may cause premature destruction of the transfused platelets. When recipients fail to demonstrate an adequate post-transfusion increment, this is termed platelet transfusion refractoriness.

Platelets, either apheresis-derived or random-donor, can be processed through a volume reduction process. In this process, the platelets are spun in a centrifuge and plasma is removed, leaving 10 to 100 mL of platelet concentrate. Such volume-reduced platelets are normally transfused only to neonatal and pediatric patients when a large volume of plasma could overload the child's small circulatory system. The lower volume of plasma also reduces the chances of an adverse transfusion reaction to plasma proteins.[84] Volume reduced platelets have a shelf life of four hours.[85]

Wound repair

[edit]
Main article: Wound repair

The blood clot is only a temporary solution to stop bleeding; tissue repair is needed. Small interruptions in the endothelium are handled by physiological mechanisms; large interruptions by a trauma surgeon.[86] The fibrin is slowly dissolved by the fibrinolytic enzyme, plasmin, and the platelets are cleared by phagocytosis.[87]

Platelets release platelet-derived growth factor (PDGF), a potent chemotactic agent; and TGF beta, which stimulates the deposition of extracellular matrix; fibroblast growth factor, insulin-like growth factor 1, platelet-derived epidermal growth factor, and vascular endothelial growth factor. Local application of these factors in increased concentrations through platelet-rich plasma (PRP) is used as an adjunct in wound healing.[88]

Non-mammals

[edit]

Instead of platelets, non-mammalian vertebrates have nucleated thrombocytes, which resemble B lymphocytes in morphology. They aggregate in response to thrombin, but not to ADP, serotonin, nor adrenaline, as platelets do.[89][90]

History

[edit]
  • George Gulliver in 1841 drew pictures of platelets[91] using the twin lens (compound) microscope invented in 1830 by Joseph Jackson Lister.[92] This microscope improved resolution sufficiently to make it possible to see platelets for the first time.
  • William Addison in 1842 drew pictures of a platelet-fibrin clot.[93]
  • Lionel Beale in 1864 was the first to publish a drawing showing platelets.[94]
  • Max Schultze in 1865 described what he called "spherules", which he noted were much smaller than red blood cells, occasionally clumped, and were sometimes found in collections of fibrin material.[95]
  • Giulio Bizzozero in 1882 studied the blood of amphibians microscopically in vivo. He named Schultze's spherules (It.) piastrine: little plates.[96][97] Bizzozero possibly proposed the name Blutplattchen.[98]
  • William Osler observed platelets and, in published lectures in 1886, called them a third corpuscle and a blood plaque; and described them as "a colorless protoplasmic disc".[99]
  • James Wright examined blood smears using the stain named for him, and used the term plates in his 1906 publication,[100] changing to platelets in his 1910 publication.[101]

See also

[edit]
Wikimedia Commons has media related to platelets.

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Platelet

View on Grokipedia
from Grokipedia
Platelets, also known as thrombocytes, are the smallest cellular components of , measuring approximately 2 to 4 micrometers in diameter and lacking a nucleus. They are anucleate fragments derived from megakaryocytes in the and circulate in the bloodstream for an average lifespan of 7 to 10 days. Essential for maintaining vascular integrity, platelets primarily function in by forming clots to prevent excessive bleeding following vascular injury. Structurally, platelets feature a plasma membrane rich in receptors such as glycoprotein Ib (GPIb), GPVI, and GPIIb/IIIa, which facilitate adhesion to damaged endothelium and aggregation with other platelets. Internally, they contain alpha granules storing proteins like von Willebrand factor (vWF), P-selectin, and clotting factors (V, IX, XIII), as well as dense granules holding calcium, ADP, ATP, serotonin, and potassium. Upon activation—triggered by stimuli like collagen exposure, thrombin, or ADP—platelets undergo shape changes from discoid to spherical, extend pseudopods, and release granule contents including thromboxane A2 and ADP to amplify aggregation and initiate the coagulation cascade, ultimately forming a stable fibrin-platelet plug. Beyond hemostasis and thrombosis, platelets contribute to diverse physiological processes, including inflammation through the release of chemokines and cytokines, immune responses via interactions with leukocytes and complement components, and tissue repair by supplying growth factors that promote angiogenesis and wound healing. Dysfunctions in platelet number or function, such as thrombocytopenia or impaired aggregation, can lead to bleeding disorders, while excessive activity is implicated in thrombotic conditions like atherosclerosis and myocardial infarction. Daily production in humans maintains a normal circulating count of 150,000 to 450,000 platelets per microliter of blood, regulated by thrombopoietin to meet demands for hemostatic balance.

Overview

Definition and Etymology

Platelets, also known as thrombocytes, are small, anucleate cell fragments derived from megakaryocytes in the that circulate in the bloodstream and are essential for through their role in blood clot formation. They represent the smallest cellular components in , lacking a nucleus and possessing limited metabolic activity compared to full cells. In their resting state, platelets exhibit a disc-shaped morphology, with a typical of 2–4 μm, enabling efficient circulation and rapid response to vascular injury. This allows them to maintain a low profile in flowing blood while facilitating adhesion to damaged when needed. The normal concentration of platelets in adult human blood ranges from 150,000 to 450,000 per microliter, varying slightly by age, sex, and health status; levels outside this range can impair clotting efficiency. The term "platelet" derives from the French "plaquette," a diminutive form of "plaque" meaning "small plate," which captures their characteristic discoid shape observed under . This was introduced in 1882 by Italian pathologist Giulio Bizzozero, who described these elements as distinct blood components and used equivalent terms like "piastrine" in Italian and "Blutplättchen" in German to highlight their form across languages. In contrast, "thrombocyte" originates from "thrombos" (clot) and "kytos" (cell), underscoring their functional role in rather than morphology; the term entered scientific usage in the 1890s.

Clinical Importance

Platelets play a pivotal role in preventing excessive and maintaining vascular integrity by rapidly responding to endothelial damage, adhering to exposed subendothelial matrix, and forming stable hemostatic plugs that seal vascular breaches. This function is essential for normal , as platelet dysfunction—whether due to quantitative deficiencies like or qualitative defects in activation and aggregation—can precipitate severe disorders or pathological , impacting millions of individuals globally each year through conditions such as immune thrombocytopenia (ITP) and . Platelet disorders are a significant contributor to admissions related to events, with alone observed in up to 50% of hospitalized patients, often complicating critical care and necessitating interventions like platelet transfusions, which occur in approximately 3.9% of pediatric hospitalizations. Beyond , platelets are indispensable in clinical management across , trauma, and , where antiplatelet therapies such as aspirin and clopidogrel reduce the risk of thrombotic complications, preventing an estimated 20-30% of recurrent ischemic events in high-risk populations. The fundamental role of platelets in exhibits remarkable evolutionary conservation, with hemostatic mechanisms involving nucleated thrombocytes—functional homologs of mammalian platelets—present across all vertebrates, from jawless fish to mammals, highlighting their universal adaptation for vascular repair over 450 million years of . This conservation underscores the indispensable nature of platelet-like cells in preventing hemorrhage in diverse physiological contexts. As of 2025, emerging research has illuminated additional clinical dimensions of platelets, particularly their involvement in thrombotic complications of , where sustained low-grade drives persistent platelet activation, exacerbating microvascular damage and pulmonary impairment in affected patients. Furthermore, platelets promote cancer by shielding circulating tumor cells from immune surveillance and facilitating their adhesion to distant , positioning them as potential therapeutic targets in to curb metastatic spread.

Structure and Development

Morphology and Ultrastructure

Platelets in their resting state exhibit a biconvex discoid morphology, measuring approximately 2-3 μm in diameter and 0.5-1 μm in thickness, which allows them to circulate efficiently through the bloodstream. These anucleate cell fragments lack a nucleus and most organelles typical of nucleated cells, yet possess a robust internal architecture essential for their structural integrity. The plasma membrane envelops the platelet and is rich in glycoproteins, such as the GP Ib-IX-V complex, which spans the membrane and contributes to surface receptor distribution. This membrane is asymmetrical, with phospholipids like phosphatidylserine sequestered in the inner leaflet to maintain a non-procoagulant surface. The of resting platelets includes two prominent membrane systems derived during their formation from megakaryocytes. The open canalicular system (OCS) consists of a network of open invaginations connected to the , forming tubules and vesicles that increase the effective surface area and facilitate internal compartmentalization. In contrast, the dense tubular system (DTS), originating from the smooth of megakaryocytes, forms a closed tubular network throughout the , serving as a reservoir for calcium ions. These systems, visible under electron microscopy, occupy significant portions of the platelet's volume and underscore its specialized design for rapid responses. Platelets contain three main types of granules, each with distinct contents and electron-dense appearances. Alpha granules, the most numerous (about 50-60 per platelet), are elongated structures measuring 200-400 nm, housing proteins such as fibrinogen, (PDGF), , and P-selectin. Dense granules, fewer in number (3-8 per platelet) and smaller (around 150 nm), appear as osmiophilic bodies and store non-protein mediators including (ADP), serotonin, and high concentrations of calcium. Lysosomes, intermediate in size (200-250 nm), contain hydrolytic enzymes like and cathepsins within an acidic milieu. These granules are distributed throughout the cytoplasm, often near the OCS. The of resting platelets provides the framework for maintaining the discoid shape and resisting circulatory shear forces. It comprises a marginal band of 8-12 encircling the periphery, an filament network (about 40-45% of total protein), and spectrin-based linkages that anchor glycoproteins like GP Ib-IX-V via filamin. and other motor proteins integrate with this system, enabling structural stability without active contraction in the resting state. This microtubular and microfilament organization, observable via high-resolution imaging, distinguishes platelets from other blood cells and supports their compact form.

Origin from Megakaryocytes

Platelets originate primarily from , large cells derived from hematopoietic stem cells (HSCs) in the , though significant contributions come from extramedullary sites such as the lungs, where resident in the pulmonary vasculature produce a substantial portion of circulating platelets (estimated at up to 50% in some studies as of 2023). development begins with HSCs differentiating through committed progenitors, including the colony-forming unit-megakaryocyte (CFU-Meg), a stage where cells are primed for the megakaryocytic lineage. This process is primarily regulated by thrombopoietin (TPO), a that binds to the c-Mpl receptor on HSCs, progenitors, and mature , activating signaling pathways such as JAK2-STAT5 to promote proliferation, differentiation, and . During maturation, undergo endomitosis, a modified involving without , leading to with DNA contents ranging from 4N to as high as 128N, which enables the synthesis of vast amounts of platelet-specific proteins and membranes. Mature megakaryocytes, typically 50-100 μm in diameter, form platelets through proplatelet extension, a process where they migrate to the endothelium and extend long, branching cytoplasmic projections called proplatelets into the sinusoidal blood vessels. These proplatelets, supported by sliding and cytoskeleton dynamics, undergo fragmentation driven by blood shear forces, releasing platelet precursors into the circulation. In humans, this biogenesis produces approximately 10^{11} platelets per day, with each yielding thousands of platelets, ensuring steady-state maintenance of circulating platelet counts between 150 × 10^9 and 400 × 10^9 per liter. Once in circulation, platelets have a lifespan of 7-10 days, during which about one-third are transiently sequestered in the spleen's sinusoids, serving as a reserve pool that can be mobilized during stress. is marked by mitochondrial dysfunction, including increased production and altered , which trigger exposure on the platelet surface. Aged platelets are primarily cleared by macrophages in the liver and via , preventing their accumulation and maintaining hemostatic balance. TPO levels further regulate this lifecycle by binding to c-Mpl receptors on circulating platelets, where it is internalized and degraded, thereby modulating free TPO availability to fine-tune production and prevent overproduction. This feedback mechanism ensures that platelet biogenesis matches daily turnover, with TPO concentrations inversely correlating with platelet mass.

Functions in

Adhesion

Platelet adhesion represents the initial step in , where circulating platelets tether and attach to the subendothelial matrix exposed upon vascular injury. Under conditions of high , such as in arterial blood flow exceeding 1000 s⁻¹, (vWF) plays a pivotal role in mediating this process. Immobilized vWF on the damaged vessel wall unfolds in response to hydrodynamic forces, exposing binding sites that interact with the glycoprotein Ib-IX-V (GPIb-IX-V) complex on the platelet surface, thereby tethering platelets to the subendothelium and enabling rolling adhesion. This GPIb-IX-V/vWF interaction is shear-dependent, becoming essential at arterial shear rates where direct platelet-subendothelium contact is limited by flow dynamics. In parallel, exposure of subendothelial further stabilizes platelet through specific receptor-ligand interactions. The platelet receptor glycoprotein VI (GPVI) binds directly to collagen fibrils, initiating signaling that promotes firm attachment, while the α₂β₁ also engages collagen to reinforce under flow conditions. These receptors operate somewhat independently, with GPVI driving activation-dependent and α₂β₁ contributing to mechanical stability on collagen surfaces. The dynamics of platelet-vWF bonds under shear are governed by force-dependent kinetics, where bond lifetime determines efficiency. At high shear rates, the dissociation rate (k_off) increases, but the bond lifetime τ, approximated as τ = 1/k_off, allows transient tethers that facilitate platelet capture before dissociation. This reversible interaction transitions to firm as inside-out signaling activates the α_{IIb}β₃, enabling platelet spreading on the surface and subsequent hemostatic plug formation. τ=1koff\tau = \frac{1}{k_{\text{off}}}

Activation

Platelet activation is the process by which circulating discoid platelets undergo rapid functional and morphological transformations in response to vascular injury, enabling their participation in hemostasis. This activation is primarily triggered by soluble agonists and adhesive interactions, which engage specific receptors on the platelet surface to initiate intracellular signaling cascades. Key triggers include , which binds to protease-activated receptors PAR1 and PAR4, leading to G protein-coupled signaling; ADP, acting through P2Y1 and receptors to mobilize calcium and inhibit , respectively; , which engages the TP receptor to promote activation; and , recognized by the GPVI receptor to initiate pathways. These agonists often arise from initial events at injury sites, amplifying the response through loops. Upon receptor engagement, signaling cascades converge on phospholipase C β (PLCβ) activation, which hydrolyzes (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of intracellular calcium from dense tubular systems, while DAG activates (PKC), promoting further downstream effects. Parallel amplification occurs via phosphatidylinositol 3-kinase (PI3K) pathways, which generate phosphoinositide to sustain signaling and enhance granule mobilization. The immediate consequences of these cascades include a dramatic shape change, where platelets transition from a smooth discoid form to an irregular with extended pseudopods, increasing surface area for interactions; secretion of alpha and dense granules, releasing additional agonists like ADP and serotonin; and conformational activation of , priming platelets for stable adhesion. To prevent excessive activation, endogenous inhibitory mechanisms counteract these pathways, primarily through endothelial-derived factors such as (NO) and (PGI2). NO activates guanylyl cyclase to elevate cyclic GMP (cGMP), which inhibits calcium mobilization, while PGI2 stimulates adenylate cyclase via IP receptors to increase cyclic AMP (cAMP), activating (PKA) and suppressing PLC and PKC activities. These cyclic nucleotide elevations synergistically dampen platelet reactivity, maintaining vascular .

Aggregation

Platelet aggregation is the process by which activated platelets adhere to one another, forming a stable plug at the site of vascular injury through intercellular bridging mediated primarily by the integrin αIIbβ3 (also known as GPIIb/IIIa). Upon platelet activation, inside-out signaling induces a conformational change in αIIbβ3 from a low-affinity bent state to a high-affinity extended state, enabling it to bind soluble plasma ligands such as fibrinogen and (vWF). This binding cross-links adjacent platelets, as fibrinogen and vWF are multivalent, allowing one molecule to simultaneously engage αIIbβ3 on multiple cells. Ligand engagement in turn triggers outside-in signaling through αIIbβ3, which reinforces platelet spreading, granule release, and clot retraction, thereby stabilizing the aggregate. Aggregation is amplified and sustained by positive feedback loops involving mediators released from activated platelets. Adenosine diphosphate (ADP), secreted from dense granules, binds to P2Y1 and receptors on nearby platelets, enhancing calcium mobilization and αIIbβ3 activation to promote further recruitment. Similarly, (TXA2), generated via cyclooxygenase-1 from in platelet membranes, acts in an autocrine and paracrine manner to induce shape change and amplify aggregation through TP receptors, with its short ensuring localized effects. These secondary agonists create a rapid escalation, converting initial weak interactions into a robust platelet mass. Activated platelets synergize with the coagulation cascade by exposing negatively charged phospholipid surfaces, particularly , which serve as platforms for the assembly of procoagulant complexes. This facilitates the binding of factor Va and factor Xa to form the prothrombinase complex, dramatically accelerating the conversion of prothrombin to —up to 300,000-fold more efficient than in solution. The generated not only cleaves fibrinogen to but also feeds back to activate additional platelets via protease-activated receptors, linking primary to secondary fibrin stabilization. Initial platelet aggregation is often reversible, characterized by weak, transient bridges that can disaggregate if levels wane, but it becomes irreversible upon polymerization, which covalently reinforces the . This transition is modeled kinetically by the rate of aggregate formation, approximated as a second-order dependent on platelet and fibrinogen availability: dPdt=k[P]2[F]\frac{dP}{dt} = k [P]^2 [F] where PP represents activated platelets, FF is fibrinogen concentration, and kk is the rate constant reflecting αIIbβ3-mediated bridging efficiency.

Immune and Inflammatory Functions

Immunothrombosis

Immunothrombosis refers to the coordinated activation of and innate immune responses, where platelets play a pivotal role in linking to pathogen defense. Upon encountering or tissue damage, activated platelets express P-selectin on their surface, which binds to (PSGL-1) on neutrophils, facilitating platelet-neutrophil aggregates that promote the release of (NETs). These NETs, composed of decondensed and proteins, capture and provide a scaffold for deposition, thereby enhancing clot formation and localizing . This interaction not only amplifies thrombotic responses but also contributes to the procoagulant environment in inflammatory conditions. Platelets further contribute to innate immunity by directly engaging bacterial pathogens through toll-like receptors (TLRs), such as TLR2 and TLR4, which recognize pathogen-associated molecular patterns. This binding triggers platelet activation, leading to the release of and the formation of microthrombi that trap , thereby enhancing by neutrophils and macrophages. In this process, platelets act as sentinels, bridging immune surveillance and to contain microbial dissemination. In severe infections like , platelet hyperactivation exacerbates immunothrombosis, culminating in (DIC), a systemic characterized by widespread microvascular and consumption of clotting factors. While this response initially limits pathogen spread by forming protective thrombi, dysregulated immunothrombosis can impair microcirculation, leading to organ ischemia and multi-organ failure. Thus, the dual nature of platelet-mediated immunothrombosis underscores its essential yet potentially detrimental role in balancing infection control against tissue integrity.

Role in Inflammation

Platelets contribute to inflammatory processes through the release of soluble mediators stored in their granules, which modulate leukocyte recruitment and endothelial activation. Upon activation, platelets secrete interleukin-1β (IL-1β), which binds to IL-1 receptors on monocytes and leukocytes, promoting their mobilization and adhesion to the vascular wall. Similarly, platelet-derived (also known as , PF4) enhances endothelial activation by upregulating adhesion molecules and chemokines, facilitating into inflamed tissues. Additionally, soluble CD40 ligand (sCD40L) released from activated platelets interacts with CD40 on endothelial cells and immune cells, amplifying pro-inflammatory signaling and production. Beyond soluble factors, platelets directly bridge leukocytes to the , forming aggregates that intensify local . Platelet-monocyte aggregates primarily form through the interaction of P-selectin expressed on activated platelets with (PSGL-1) on s, stabilizing these complexes and promoting monocyte activation and tissue infiltration. This bridging mechanism enhances inflammatory responses by increasing monocyte adhesion to endothelial , thereby supporting sustained leukocyte-endothelial interactions independent of formation. Platelet-derived further reinforce this process by directing monocyte toward inflamed sites. In chronic inflammatory conditions like , platelets drive plaque formation by promoting development. Activated platelets release factors that induce differentiation into macrophages, which then uptake oxidized (ox-LDL) to form lipid-laden s, a hallmark of atherosclerotic lesions. This process is exacerbated by platelet-derived mediators that enhance ox-LDL internalization by macrophages, contributing to plaque progression and instability. Platelets also participate in the resolution phase of by generating lipid mediators through interactions with endothelial cells. During the later stages of inflammatory responses, platelet-endothelium transcellular produces s, such as lipoxin A4 (LXA4), which inhibit excessive leukocyte recruitment and promote of apoptotic cells without triggering further . These s counteract pro-inflammatory signals, facilitating tissue repair and restoring vascular .

Adaptive Immune Interactions

Platelets contribute to adaptive immune responses through their ability to present antigens via (MHC) class I molecules, thereby interacting with CD8+ T cells. Human platelets express and possess the necessary machinery to internalize, process, and cross-present exogenous antigens, such as those derived from pathogens, directly to naïve CD8+ T cells, leading to their activation and proliferation. This process is particularly relevant in viral immunity, where platelets enhance responses against virus-infected cells by presenting viral peptides in the context of MHC class I, thereby amplifying antiviral defenses. In addition, platelets regulate function through the release of soluble CD40 ligand (sCD40L), a key mediator of adaptive immunity. Upon activation, platelets shed sCD40L, which binds to CD40 on , promoting their proliferation, isotype switching, and differentiation into plasma cells that produce high-affinity . This platelet-derived sCD40L enhances by supporting T-dependent antibody responses and has been shown to increase immunoglobulin production . Platelets also interact with the in autoimmune contexts, where they can become targets of pathogenetic antibodies. In immune thrombocytopenia (ITP), autoantibodies against platelet glycoproteins, produced by B cells, lead to platelet clearance and destruction, highlighting the capacity to target platelets. Similarly, in vaccine-induced immune thrombotic (VITT), observed after certain adenoviral vector-based vaccinations like in 2021, anti-platelet factor 4 (PF4) antibodies activate platelets via Fcγ receptors, resulting in and . Furthermore, platelets participate in allergic responses mediated by adaptive immunity through IgE-dependent mechanisms. Human platelets express the high-affinity IgE receptor FcεRI, allowing direct activation by allergen-bound IgE, which triggers platelet degranulation and contributes to the amplification of anaphylactic reactions by releasing vasoactive mediators. This IgE-mediated platelet activation enhances systemic inflammation and hypotension during anaphylaxis, underscoring platelets' role in bridging adaptive humoral responses with immediate hypersensitivity.

Laboratory Measurement and Testing

Platelet Quantification

Platelet quantification primarily involves determining the number of platelets in the , often as part of a (CBC), which provides essential parameters for assessing platelet production and function. Automated analyzers are the standard method for platelet counting, employing either or optical techniques to measure platelet concentration with high throughput and precision. In the impedance method, platelets passing through an aperture generate electrical pulses proportional to their volume, allowing differentiation from red cells based on size. Optical methods, such as light scatter or , detect platelets by analyzing forward and side scatter or with fluorescent dyes to identify cellular components. The normal platelet count in healthy adults ranges from 150 to 450 × 10⁹/L, serving as a key reference for diagnosing thrombotic or hemorrhagic disorders. Manual platelet counting remains a reference standard, particularly for verifying automated results in cases of suspected artifacts, and is performed using on a stained with Wright-Giemsa or similar dyes. This technique involves counting platelets in multiple microscopic fields and calculating the count per microliter based on the count, offering insights into platelet morphology alongside quantity. Automated analyzers also derive the (MPV), which measures the average size of platelets and typically falls between 7 and 11 femtoliters (fL) in healthy individuals, providing additional context on platelet maturity and turnover. The immature platelet fraction (IPF), measured via , quantifies the proportion of newly released, reticulated platelets—those containing residual —within the total platelet population, expressed as a (normal range 1–7%). This parameter, detected using fluorescent dyes like thiazole orange that bind to , serves as a non-invasive indicator of thrombopoietic activity and platelet production rate, aiding in distinguishing between underproduction and increased destruction of platelets. A notable limitation in platelet quantification is , an artifact where platelets clump in EDTA-anticoagulated blood samples, leading to falsely low counts due to antibody-mediated aggregation at . This affects up to 0.1–2% of samples and can be mitigated by using alternative anticoagulants like citrate or performing counts at 37°C, ensuring accurate interpretation.

Functional Assays

Functional assays evaluate the reactivity and hemostatic potential of platelets, providing insights into their ability to contribute to clot formation beyond mere quantification. These tests assess platelet function in response to stimuli, helping diagnose disorders of primary and monitor antiplatelet therapy efficacy. Common methods include and approaches that measure adhesion, activation, and aggregation under controlled conditions. The test, using the Ivy or template method, measures the time required for primary by creating a standardized incision on the while maintaining venous at 40 mmHg; normal values range from 2 to 9 minutes. This evaluates the integrated function of platelets and vascular in forming a hemostatic plug. However, it has largely fallen out of use due to high inter- and intra-operator variability, low sensitivity for detecting mild platelet defects, and lack of standardization, with many institutions discontinuing it without impacting clinical outcomes. VerifyNow is a point-of-care turbidimetric that quantifies platelet reactivity in to assess responses to aspirin and clopidogrel. It uses cartridge-based systems where activated platelets bind fibrinogen-coated beads, causing changes in light transmission proportional to aggregation; results are reported in aspirin reaction units (ARU) or P2Y12 reaction units (PRU). For aspirin, ARU below 550 indicates effective inhibition, while PRU above 208 suggests high on-treatment platelet reactivity to clopidogrel. This rapid test (results in 5-10 minutes) aids in identifying non-responders to antiplatelet in cardiovascular patients. As of 2024, the International Consensus Statement recommends platelet function testing to guide inhibitor selection in high-risk PCI patients to optimize ischemic and bleeding risk balance. Flow cytometry detects platelet activation markers, such as surface expression of P-selectin (CD62P), following stimulation with agonists like or ADP. In this method, fluorescently labeled antibodies bind to activated platelets in or , allowing quantification of and receptor conformational changes via light and detection. It provides high sensitivity for early activation events and can assess multiple markers simultaneously, including fibrinogen binding to GPIIb/IIIa, making it valuable for research and diagnosing inherited platelet disorders. Thromboelastography (TEG) assesses overall clot strength, including the platelet contribution to viscoelastic properties in . The assay involves rotating a pin in a cup of kaolin-activated , tracing clot formation kinetics; the maximum amplitude (MA) parameter reflects clot firmness, with platelet-fibrinogen interactions accounting for about 80% of MA. Modified TEG with GPIIb/IIIa inhibitors isolates platelet function by eliminating contributions, aiding in transfusion guidance during or trauma. This global test correlates platelet reactivity with clinical risk better than isolated aggregation assays.

Specific Aggregometry Methods

Light transmission aggregometry (LTA) serves as the gold standard for assessing platelet aggregation, measuring changes in light through (PRP) as platelets clump together in response to specific agonists. Introduced in , this optical method detects an increase in light transmission as aggregated platelets settle, forming a curve that quantifies the aggregation response; commonly used agonists include (ADP), , epinephrine, and . In PRP prepared by from citrated , a baseline transmittance is established against platelet-poor plasma, and aggregation is induced, allowing for precise evaluation of platelet function in isolated settings. Whole blood impedance aggregometry, exemplified by the Multiplate analyzer, evaluates platelet aggregation directly in hirudin-anticoagulated by measuring electrical resistance between electrodes as platelets adhere and form aggregates on their surfaces. This method avoids the need for PRP preparation, using small blood volumes (typically 300 μL per test) and providing results within minutes; it employs agonists such as ADP, thrombin receptor-activating (TRAP), and to stimulate aggregation, with impedance changes converted to arbitrary aggregation units (AU). The technique is particularly useful for point-of-care or rapid laboratory assessments, correlating well with LTA in detecting aggregation responses while preserving the physiological context of components like red cells and plasma. Multiple aggregometry (MEA), often performed using the , extends impedance principles by incorporating multiple pairs in a single test to enhance and sensitivity in monitoring platelet reactivity, especially under antiplatelet therapy. This approach quantifies aggregation through dynamic changes in upon agonist addition, with protocols tailored to evaluate inhibition by drugs like aspirin or P2Y12 inhibitors; for instance, ADPtest and ASPI test cartridges assess specific pathways. MEA's format minimizes pre-analytical variables and facilitates high-throughput testing, showing strong agreement with LTA for agonist-induced responses in clinical cohorts. Interpretation of aggregometry tracings focuses on key curve parameters: the lag phase (initial delay before aggregation begins), the (rate of aggregation, reflecting primary response ), and maximum (peak aggregation extent, indicating overall platelet reactivity). In LTA, normal ADP-induced aggregation typically reaches 60-100% of maximum change, while reduced values signal dysfunction or therapy effects; similar metrics in impedance methods yield area under the curve (AUC) in AU·min, with reference ranges varying by agonist and device (e.g., >50 AU·min for ADP in MEA). These parameters provide a standardized framework for diagnosing aggregation defects, though results must account for variables like platelet count and type.

Point-of-Care Tests

Point-of-care (POC) tests for platelet function provide rapid assessments at the bedside, enabling timely clinical decisions in settings requiring immediate evaluation. These assays utilize samples and simulate physiological conditions to measure platelet adhesion, aggregation, and overall contribution to clot formation, typically yielding results within minutes. Unlike laboratory-based methods such as light transmission aggregometry, POC tests prioritize speed and simplicity for perioperative or emergency use. The (PFA-100 and its successor PFA-200) is a widely used POC device that evaluates platelet function under high conditions mimicking primary . Citrated is aspirated through a tube onto a membrane coated with and either epinephrine (CEPI) or ADP (CADP), where platelets adhere and aggregate to form a that occludes the ; the closure time (CT) is recorded as the endpoint. Normal CT values are typically less than 180 seconds for both cartridges, with prolongation indicating defects in platelet function or von (vWF). The assay is particularly sensitive to vWF deficiencies, aspirin effects on the CEPI cartridge, and P2Y12 inhibitor impacts on the CADP or P2Y cartridges in the PFA-200 model. Emerging microfluidic POC tests and AI-integrated are advancing rapid platelet function assessment as of 2024. Thromboelastography (TEG) with PlateletMapping extends viscoelastic testing to specifically quantify platelet function and detect effects. In this , whole blood is activated with kaolin to initiate , followed by addition of activators such as (for aspirin sensitivity) or ADP (for inhibitors like clopidogrel); the maximum (MA) of the clot trace is compared between activator-induced and fibrinogen-mediated responses to calculate percent inhibition. This approach identifies specific inhibitor effects, with normal platelet contributions yielding MA values of 50-70 mm depending on the agonist. TEG PlateletMapping integrates platelet assessment into broader profiling, aiding in the differentiation of drug-induced dysfunction from other coagulopathies. POC platelet function tests offer key advantages, including turnaround times of 5-10 minutes, minimal sample processing with direct use, and portability for bedside application. They are particularly valuable in for guiding transfusion strategies and reducing blood loss by identifying residual antiplatelet effects preoperatively, as well as in neurointervention procedures like clipping or flow diversion where rapid assessment of bleeding risk is critical to optimize outcomes such as reduced hemorrhagic events and shorter hospital stays.

Platelet Disorders

Thrombocytopenia

Thrombocytopenia is defined as a platelet count below 150 × 10⁹/L in adults. This condition impairs by reducing the availability of platelets necessary for clot formation. Severe thrombocytopenia, with counts below 20 × 10⁹/L, significantly increases the risk of spontaneous due to insufficient formation at injury sites. The causes of thrombocytopenia are broadly categorized into decreased production, increased destruction or consumption, and sequestration in the . Decreased production arises from disorders such as , where limits platelet generation, or from thrombopoietin (TPO) deficiency, a rare condition impairing maturation and proliferation. Other production defects include nutritional deficiencies like or shortage and suppression by drugs such as agents. Increased destruction commonly occurs in immune thrombocytopenia (ITP), an autoimmune disorder where antibodies target platelets for splenic clearance, or in drug-induced cases like (). Sequestration, often due to hypersplenism in conditions like , traps up to one-third of platelets in an enlarged , reducing circulating levels without altering production or destruction rates. Symptoms of thrombocytopenia primarily manifest as bleeding tendencies proportional to the severity of the platelet reduction. Mild cases may be , but moderate to severe thrombocytopenia often presents with cutaneous signs such as petechiae (small red or purple spots from bleeding) and (larger areas of discoloration). Mucosal bleeding, including epistaxis and gingival hemorrhage, is common, along with prolonged after minor trauma due to delayed primary . In severe instances, gastrointestinal or can occur, posing life-threatening risks. Diagnosis begins with a (CBC) to confirm low platelet counts, often followed by a peripheral blood smear to exclude from clumping. The immature platelet fraction (IPF), measured via automated analyzers, helps differentiate production defects (low IPF) from destruction or sequestration (high IPF), guiding further evaluation. is indicated when production issues are suspected, revealing decreased megakaryocytes in hypoproliferative states like versus normal or increased numbers in destructive causes like ITP. Additional tests, such as anti-platelet antibody assays or infection screening, target specific etiologies.

Thrombocytosis

Thrombocytosis is defined as an elevated platelet count exceeding 450 × 10⁹/L in peripheral blood, distinguishing it from the normal range of 150–450 × 10⁹/L. This condition is broadly classified into two categories: reactive (secondary) thrombocytosis, which arises from underlying non-malignant processes, and primary thrombocytosis, a clonal disorder stemming from (MPNs). Reactive thrombocytosis is far more common, accounting for the majority of cases, and typically resolves upon treatment of the underlying cause. Reactive thrombocytosis is triggered by various physiological responses, including infections (such as bacterial or viral illnesses), chronic inflammation (e.g., or ), iron deficiency anemia, tissue damage from surgery or trauma, and hyposplenism following . These conditions elevate thrombopoietin levels or stimulate megakaryopoiesis indirectly, leading to increased platelet production without intrinsic bone marrow abnormalities. In contrast, primary thrombocytosis results from autonomous proliferation of megakaryocytes due to acquired genetic mutations in hematopoietic stem cells. (ET), a key MPN associated with primary thrombocytosis, is characterized by persistent thrombocytosis and often involves the JAK2 V617F mutation in approximately 50–60% of cases, which activates the and promotes unchecked megakaryocyte growth. Other primary causes include and , though ET is the most frequent isolated cause of primary thrombocytosis. The primary clinical concern in thrombocytosis, particularly the primary form, is the heightened risk of thrombotic complications, which outweighs risks in most patients. Arterial (e.g., or ) and venous (e.g., or ) occur at rates significantly elevated in ET, with annual incidence up to 2–3% in affected individuals, driven by platelet hyperaggregability and . Microvascular disturbances, such as —a burning pain and redness in the extremities due to arteriolar occlusion—manifest in up to 20–30% of ET patients and correlate with platelet counts above 400 × 10⁹/L. Paradoxical , though less common, can arise in extreme thrombocytosis (>1,000 × 10⁹/L) due to acquired deficiency from platelet-mediated . Management of thrombocytosis emphasizes distinguishing reactive from primary forms through clinical history, laboratory evaluation (including bone marrow if indicated), and addressing reversible causes in reactive cases. For primary thrombocytosis like ET, risk stratification guides intervention: very low-risk patients (age ≤60 years, no history, JAK2 wild-type) require observation or low-dose aspirin alone, while high-risk patients (age >60 years or prior ) warrant cytoreductive therapy to reduce platelet counts below 400 × 10⁹/L and mitigate thrombotic events. Cardiovascular risk factors, such as or , further inform stratification to optimize outcomes.

Qualitative Function Defects

Qualitative function defects of platelets refer to impairments in platelet activity that occur despite normal platelet counts, leading to defective and increased risk. These defects can be inherited or acquired, disrupting key processes such as , , aggregation, or . Inherited disorders typically manifest from birth with lifelong tendencies, while acquired ones arise secondarily to underlying conditions or procedures and are often reversible with treatment of the primary cause. Inherited qualitative platelet function defects include rare autosomal recessive disorders that affect specific glycoprotein receptors essential for platelet function. Glanzmann thrombasthenia, caused by mutations in the ITGA2B or ITGB3 genes leading to quantitative or qualitative deficiencies in the αIIbβ3 (GPIIb/IIIa), impairs fibrinogen binding and subsequent platelet aggregation. Patients with this condition experience mucocutaneous , such as epistaxis and gingival hemorrhage, starting from birth or early childhood. Another example is Bernard-Soulier syndrome, resulting from mutations in GPIBA, GPIBB, or GP9 genes that cause deficiency of the GPIb-IX-V complex, which is crucial for platelet adhesion to . This leads to prolonged bleeding times and giant platelets, with symptoms including easy bruising, , and excessive after minor trauma, also evident from birth. Acquired qualitative platelet function defects arise from systemic conditions or medical interventions that alter platelet reactivity without affecting counts. , common in , induces platelet dysfunction through uremic toxins that impair adhesion and aggregation, contributing to prolonged . during causes transient platelet activation and loss of Ib/IX function due to and contact with artificial surfaces, resulting in reversible hemostatic impairment. Antiplatelet drugs, such as aspirin or inhibitors, can also induce acquired defects by inhibiting specific activation pathways, though these are often intentional and reversible upon discontinuation. These acquired defects are generally correctable by addressing the underlying cause, such as dialysis for or supportive measures during bypass. Clinically, qualitative platelet function defects present with excessive or prolonged following , , or spontaneous events like epistaxis, despite normal platelet counts on routine testing. Mucocutaneous is prominent in inherited cases, while acquired defects may manifest perioperatively or in hospitalized patients with comorbidities. relies on specific functional assays, such as light transmission aggregometry (LTA), which serves as the gold standard to detect absent or reduced responses to agonists like ADP or in disorders such as Glanzmann thrombasthenia, or selective impairment with in Bernard-Soulier syndrome. can further confirm receptor deficiencies, guiding targeted management.

Pharmacology

Antiplatelet Drugs

Antiplatelet drugs are pharmacological agents designed to inhibit platelet activation and aggregation, thereby reducing the risk of thrombotic events such as and . These medications target key pathways in platelet function, including synthesis and ADP-mediated signaling, to prevent excessive clot formation in arterial diseases. They are cornerstone therapies in managing acute coronary syndromes (ACS) and following percutaneous coronary interventions (PCI), where dual antiplatelet therapy (DAPT) combining aspirin with a P2Y12 inhibitor is standard. Oral antiplatelet agents form the foundation of long-term . Aspirin, an irreversible inhibitor of cyclooxygenase-1 (COX-1), acetylates the to block the production of (TXA2), a potent platelet aggregator and vasoconstrictor, with effects lasting the platelet's lifespan of about 7-10 days. inhibitors, which competitively the receptor to disrupt ADP-induced platelet amplification, include clopidogrel, , and . Clopidogrel and are thienopyridines that require hepatic activation to prodrugs, providing irreversible inhibition, while is a direct-acting, reversible with faster onset and offset. Intravenous antiplatelet drugs are reserved for acute settings, such as during PCI or in high-risk ACS. (GPIIb/IIIa) antagonists, including , , and , bind to the GPIIb/IIIa receptor to prevent fibrinogen-mediated platelet cross-linking and aggregation. is a fragment with high affinity and prolonged action, whereas and are small-molecule mimics with shorter half-lives, allowing rapid reversibility. Indications for antiplatelet drugs primarily include secondary prevention in ACS, post- placement to mitigate , and prevention in certain cases when combined with anticoagulants. In ACS patients undergoing PCI, DAPT with aspirin and a inhibitor reduces recurrent ischemic events by approximately 20-30% compared to aspirin alone, based on landmark trials like CURE for clopidogrel. GPIIb/IIIa inhibitors are used adjunctively in high-risk PCI to further lower periprocedural complications, though their routine use has declined with potent oral agents. The primary associated with antiplatelet is , particularly gastrointestinal () hemorrhage, which occurs in 1-2% of patients annually on DAPT and is dose-dependent for aspirin. Aspirin increases GI bleed by inhibiting protective synthesis in the , while P2Y12 inhibitors add to this through impaired . Balancing thrombotic and risks guides duration of , often 6-12 months post-PCI. Monitoring for antiplatelet resistance, defined as inadequate inhibition of platelet function despite , is performed using point-of-care assays like VerifyNow, which quantifies response to aspirin via arachidonic acid-induced aggregation and to inhibitors via ADP pathways. High on-treatment platelet reactivity detected by VerifyNow predicts ischemic events in clopidogrel-treated patients, prompting potential dose adjustments or switches to more potent agents like or .

Thrombopoietic Stimulants

Thrombopoietic stimulants, also known as agonists (TRAs), are pharmacologic agents designed to increase platelet production by mimicking the action of endogenous thrombopoietin (TPO), addressing through enhanced megakaryopoiesis in the . These drugs bind to the c-Mpl receptor on progenitors, activating signaling pathways such as JAK-STAT that promote megakaryocyte proliferation, differentiation, and subsequent platelet release. Unlike direct platelet transfusions, TRAs target the underlying hypoproduction of platelets from megakaryocytes. Romiplostim, a recombinant TPO mimetic classified as a peptibody (an Fc-peptide fusion protein), is administered subcutaneously on a weekly basis, with an initial dose of 1 μg/kg adjusted based on platelet response to maintain counts between 50 and 200 × 10^9/L. It binds competitively to the extracellular domain of c-Mpl, stimulating megakaryopoiesis without cross-reacting with endogenous TPO. Eltrombopag, a small-molecule non-peptide agonist, is taken orally daily (typically 50 mg for adults with immune thrombocytopenia), binding to the transmembrane region of c-Mpl to activate similar intracellular pathways, though it requires adjustments for hepatic impairment or East Asian ancestry to avoid excessive dosing. Avatrombopag, another oral small-molecule non-peptide TRA, is dosed at 20 mg daily for chronic ITP, binding to the transmembrane domain of c-Mpl and offering an alternative for patients intolerant to eltrombopag due to its different metabolic pathway and lack of hepatic CYP enzyme interactions. Both romiplostim and eltrombopag (along with avatrombopag) are approved for chronic immune thrombocytopenia (ITP) as second-line therapy in adults and children who have failed corticosteroids, IVIG, or splenectomy, with romiplostim and eltrombopag also indicated for ITP in pediatric patients as young as 1 year.30153-X/fulltext) In refractory aplastic anemia, where bone marrow failure leads to pancytopenia including thrombocytopenia, eltrombopag is used in combination with immunosuppressive therapy as first-line treatment for severe cases in adults and children over 2 years, showing improved overall response rates of 68% at 6 months compared to 41% with immunosuppression alone. Romiplostim has demonstrated efficacy in refractory aplastic anemia, with platelet responses in 76% of patients at doses of 10 μg/kg weekly, often leading to multilineage hematologic recovery. Clinical response rates for these agents in chronic ITP range from 60% to 80%, with durable platelet increases enabling reduced bleeding risk and improved quality of life; for instance, romiplostim achieves responses in 75% of patients across multiple trials, while eltrombopag yields about 69%.30153-X/fulltext) Common side effects of both drugs include , , and injection-site reactions for , alongside and for , but serious risks encompass thrombotic events due to elevated platelet counts and potential reticulin , observed in up to 10% of long-term users, though typically reversible upon discontinuation. risk is higher in patients with preexisting , necessitating close monitoring of platelet levels to avoid supraphysiologic elevations above 400 × 10^9/L. Hepatic enzyme elevations occur in about 10% of users, requiring baseline and periodic , while carries a rare risk of progression to myelofibrosis in prolonged use. Overall, these agents are well-tolerated with a favorable benefit-risk profile in eligible patients.

Anti-Inflammatory Agents

Corticosteroids, such as , are widely used as first-line therapy in immune thrombocytopenia (ITP) and other autoimmune conditions involving platelet-mediated . These agents suppress the release of pro-inflammatory cytokines like interleukin-1β (IL-1β) from activated platelets, thereby reducing autoimmune destruction of platelets and mitigating . In ITP, inhibits humoral and cell-mediated immune responses that target platelets, leading to decreased IL-1β-driven inflammatory cascades and improved platelet counts. This mechanism contributes to the rapid hemostatic effects observed in autoimmune settings, where platelet-derived IL-1β exacerbates endothelial and leukocyte recruitment. Colchicine, an established anti-inflammatory drug, targets platelet-leukocyte interactions critical in conditions like and . By binding to and disrupting assembly, colchicine inhibits the adhesion of leukocytes to activated platelets, reducing the formation of platelet-leukocyte aggregates that propagate . In , this action diminishes neutrophil-platelet interactions at sites of urate crystal deposition, alleviating acute inflammatory flares. Similarly, in , colchicine's inhibition of these interactions prevents excessive pericardial , supporting its role as a adjunct therapy alongside standard treatments. Emerging therapies as of 2025 include anti-P-selectin antibodies, such as analogs of , which block P-selectin expression on platelet surfaces to prevent vaso-occlusive crises in . , a humanized , binds P-selectin to inhibit platelet-endothelial and platelet-leukocyte interactions, significantly reducing the annualized rate of vaso-occlusive events by limiting and microvascular occlusion. Ongoing developments in these analogs aim to enhance specificity and duration of action, offering targeted relief from platelet-driven inflammatory pain crises without broad . Certain antiplatelet agents exhibit dual roles by concurrently reducing through pathways like inhibition. For instance, aspirin, beyond its primary cyclooxygenase-1 inhibition, suppresses in platelets and endothelial cells, thereby decreasing pro-inflammatory production and leukocyte adhesion. This secondary effect underscores aspirin's utility in conditions where platelet fuels chronic , such as cardiovascular diseases with an inflammatory component.

Therapies

Platelet Transfusion

Platelet transfusions are a critical intervention for managing and associated risks. Prophylactic transfusions are recommended for stable hospitalized adult patients with platelet counts of 10 × 10^9/L or less to reduce the incidence of spontaneous hemorrhagic events, particularly in those with hypoproliferative such as in chemotherapy-induced states. Therapeutic transfusions are indicated in patients experiencing active due to low platelet counts or qualitative platelet defects, aiming to restore hemostatic function rapidly. In cases of platelet transfusion refractoriness, often caused by alloimmunization against (HLA) class I antigens, specialized approaches are required to achieve adequate posttransfusion increments. Platelet components are prepared through two primary methods: collection from a single donor or pooling from donations. platelets, collected via automated , yield a single-donor unit containing 3-4 × 10^11 platelets and are preferred for HLA-matched transfusions in alloimmunized patients, as matching reduces immune destruction and improves efficacy. In contrast, -derived platelets are obtained by processing buffy coats or from multiple units (typically 4-6 donors per pool), providing equivalent clinical outcomes in non- settings but with a higher of multiple donor exposures. Both types undergo bacterial testing to ensure safety before release. Storage conditions are optimized to maintain platelet viability and function. Standard room-temperature storage at 20-24°C with continuous gentle agitation preserves metabolic activity and prevents shape changes, yielding a of 5-7 days from collection. Emerging on cold storage (4-6°C) has shown promise for extending viability; by 2025, U.S. FDA guidance permits up to 14 days of cold storage for platelets used in active scenarios when conventional products are unavailable, with additives like those from Preservation Bio reducing bacterial risks and enhancing recovery. Clinical trials indicate that cold-stored platelets up to 14 days maintain noninferior hemostatic efficacy compared to 5-day room-temperature units. Administration involves intravenous infusion through a standard blood filter (170-260 μm pore size) to remove aggregates, typically over 30-60 minutes to minimize reactions. The standard adult dose is one unit or 4-6 pooled whole blood-derived units, while pediatric dosing is 10 mL/kg; a general guideline is one unit per 10 kg body weight, expected to increase the platelet count by approximately 50 × 10^9/L in non-refractory patients. Monitoring posttransfusion platelet counts 10-60 minutes after infusion helps assess response and guide further dosing.

Wound Repair and Tissue Regeneration

Platelets play a pivotal role in repair and tissue regeneration beyond their hemostatic functions, primarily through the release of bioactive molecules that orchestrate cellular responses essential for healing. (PRP) is an autologous concentrate derived from centrifuged , typically achieving a platelet concentration 4-5 times higher than baseline, which serves as a reservoir for growth factors such as (PDGF) and transforming growth factor-beta (TGF-β). These factors are instrumental in applications like tendon and musculoskeletal repair, where PRP injections enhance synthesis and cellular migration to accelerate recovery in conditions such as injuries and . Complementing PRP, (PRF) forms a solid, autologous matrix through low-speed of without anticoagulants, enabling sustained release of growth factors over 7-10 days. This matrix acts as a scaffold in for socket preservation and guided regeneration, as well as in orthopedics for and repair, promoting integration with host tissues and reducing postoperative complications. The prolonged bioactivity of PRF distinguishes it from liquid PRP, fostering a more controlled microenvironment for tissue remodeling. The regenerative mechanisms of these platelet concentrates involve stimulating via (VEGF) upregulation and promoting proliferation through PDGF and TGF-β signaling, which collectively enhance deposition and epithelialization. In referencing platelet granules briefly, alpha granules release these factors to initiate these processes. Clinical evidence from randomized controlled trials (RCTs) supports their efficacy; for instance, PRP treatment in chronic ulcers has demonstrated higher complete healing rates and reduced healing times compared to standard care. Similar benefits, including accelerated closure, are observed in venous leg ulcers. Despite these advantages, limitations persist, including variable efficacy across patient populations due to differences in underlying comorbidities and inconsistent clinical outcomes in some trials for non-diabetic wounds. Standardization issues, such as variability in protocols and platelet concentrations, further challenge , with calls for optimized preparation guidelines to enhance reliability in regenerative applications.

History and Comparative Biology

Historical Milestones

The earliest observations of platelet-like structures in blood occurred in the mid-19th century. In 1842, French pathologist Alfred Donné described small, colorless globules in fresh blood under the , referring to them as "globulins" or "hematoblasts," which were later recognized as precursors to modern understanding of platelets. A pivotal advancement came in when Italian pathologist Giulio Bizzozero provided the first comprehensive microscopic examination of these elements in the circulating blood of living animals, coining the term "piastrine" (Italian for little plates) and establishing their essential role in blood coagulation and formation. In 1910, American hematologist William W. Duke introduced the test, a simple clinical involving standardized skin punctures to measure duration, which quantitatively linked reduced platelet counts to prolonged bleeding and advanced the assessment of platelet-related hemorrhagic disorders. The 1960s and marked a surge in molecular insights into platelet function. In the early , the Ib-IX-V complex (GPIb) was identified as crucial for platelet adhesion to the subendothelium via , primarily through investigations of Bernard-Soulier patients lacking this receptor. Concurrently, in the mid-, the GPIIb/IIIa was characterized as the primary fibrinogen-binding receptor enabling platelet aggregation, based on analyses of Glanzmann thrombasthenia where its deficiency impairs clot formation. During this era, pharmacologist elucidated aspirin's mechanism in 1971, demonstrating its irreversible inhibition of cyclooxygenase-1, which blocks production and thereby suppresses platelet activation and aggregation. The 1990s brought breakthroughs in platelet production regulation. In 1994, thrombopoietin (TPO) was independently cloned by multiple teams, revealing it as the key that stimulates proliferation and maturation to maintain platelet levels. From the late 1990s into the 2000s, receptor inhibitors emerged as targeted antiplatelet agents; was approved in 1991 for preventing arterial , followed by clopidogrel in 1997, which selectively blocks ADP-mediated platelet via the receptor, significantly reducing ischemic events in cardiovascular patients. Spanning the to , the concept of immunothrombosis gained prominence, describing the protective integration of and innate immunity where platelets facilitate microbial entrapment and inflammatory signaling; early foundations in the linked factors to immune responses, with the term coined in 2013 by Engelmann and Massberg and expanded in research through the , particularly in the context of , driving a surge in publications from 2020 onward to highlight dysregulated platelet-inflammation crosstalk in diseases.

Platelets in Non-Mammals

In non-mammalian vertebrates, the functional equivalents of mammalian platelets are nucleated cells known as thrombocytes, which differ in structure and origin but share roles in . In birds and reptiles, thrombocytes are nucleated, elliptical to or oval-shaped cells, typically measuring 10-20 μm in length, larger than the anucleate mammalian platelets (2-4 μm) that enable rapid cytoplasmic release without nuclear constraints. These thrombocytes originate from multipotent hematopoietic progenitors and perform hemostatic functions similar to platelets, including adhesion to damaged , aggregation, and promotion of clot formation through the release of clotting factors. For instance, avian thrombocytes respond to and by signaling pathways that facilitate aggregation and contribute to inflammatory responses, though their nucleated nature may limit the speed of activation compared to mammalian counterparts. In and , thrombocytes exhibit an ovoid or spindle-shaped morphology with a large central nucleus occupying much of the cell volume, distinguishing them from the discoid shape of mammalian platelets. These cells, often 5-10 μm in size, participate in primarily through adhesion and limited aggregation, but their responses are generally less efficient than in higher vertebrates, with greater reliance on extrinsic pathways involving plasma factors like fibrinogen and . For example, thrombocytes aggregate in response to prostanoids and mimetics but require higher concentrations of fibrinogen for maximal clumping, and amphibian thrombocytes show phagocytic capabilities alongside modest clot initiation, underscoring a transitional role in evolution. This reduced aggregation efficiency may reflect adaptations to aquatic environments, where pressure-driven demands quicker plasma-based sealing over cellular plugs. Invertebrates lack true platelets or thrombocytes altogether, instead employing hemocytes—multifunctional immune cells in the —to manage clotting through gelation and encapsulation rather than discrete cellular aggregation. In insects and arthropods, such as and , hemocytes release enzymes that cross-link clotting proteins like clottin, forming an insoluble gel matrix to seal wounds and prevent hemolymph loss. This process involves a two-step nucleation: initial hemocyte aggregation followed by rapid rigidification, often without a dedicated hemostatic cell type, highlighting a primitive humoral-cellular that predates innovations. Unlike thrombocytes, invertebrate hemocytes integrate clotting with broad immunity, including and melanization, to combat at injury sites. From an evolutionary perspective, the shift to anucleate mammalian platelets likely arose around 220 million years ago from a rapid genetic adaptation in fragmentation, conferring advantages in rapid hemostatic response due to smaller size and higher circulating numbers compared to larger, nucleated non-mammalian thrombocytes. This innovation enhanced efficiency in high-pressure mammalian circulation, where quick cytoplasmic deployment prevents excessive blood loss. Despite structural differences, core genetic orthologs underlying platelet function are conserved across vertebrates; for instance, glycoprotein VI (GPVI) homologs like G6f in serve as collagen receptors on thrombocytes, mediating and signaling via ITAM motifs similar to mammalian pathways. Avian thrombocytes also express orthologous genes for platelet agonists, indicating deep phylogenetic conservation of activation mechanisms despite the absence of enucleation.

References

  1. https://www.ncbi.nlm.nih.gov/books/NBK557800/
  2. https://www.ncbi.nlm.nih.gov/books/NBK470328/
  3. https://www.nhlbi.nih.gov/health/thrombocytopenia
  4. https://www.ncbi.nlm.nih.gov/books/NBK262/
  5. https://www.mdpi.com/2038-8330/16/2/21
  6. https://www.sciencedirect.com/topics/neuroscience/thrombocyte
  7. https://pmc.ncbi.nlm.nih.gov/articles/PMC9653660/
  8. https://ashpublications.org/blood/article/126/5/582/126435/Platelets-at-the-interface-of-thrombosis
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC8087223/
  10. https://publications.aap.org/hospitalpediatrics/article/13/4/283/190812/Epidemiology-of-Platelet-Transfusions-in
  11. https://www.aafp.org/pubs/afp/issues/2017/1001/p436.html
  12. https://pmc.ncbi.nlm.nih.gov/articles/PMC2793433/
  13. https://bmcecolevol.biomedcentral.com/articles/10.1186/s12862-015-0409-y
  14. https://pmc.ncbi.nlm.nih.gov/articles/PMC11830243/
  15. https://pmc.ncbi.nlm.nih.gov/articles/PMC12572930/
  16. https://www.ncbi.nlm.nih.gov/books/NBK53455/
  17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3960550/
  18. https://www.nature.com/articles/s41467-023-39598-9
  19. https://ashpublications.org/blood/article/143/3/192/507084/Megakaryocytes-in-the-lung-guests-or-ghosts
  20. https://pmc.ncbi.nlm.nih.gov/articles/PMC6594866/
  21. https://pmc.ncbi.nlm.nih.gov/articles/PMC8292222/
  22. https://pmc.ncbi.nlm.nih.gov/articles/PMC3678154/
  23. https://pubmed.ncbi.nlm.nih.gov/16805859/
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC3976218/
  25. https://pmc.ncbi.nlm.nih.gov/articles/PMC6447301/
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC2921562/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC12382986/
  28. https://pubmed.ncbi.nlm.nih.gov/10460590/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC4284388/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC9378482/
  31. https://www.ahajournals.org/doi/10.1161/01.res.0000267878.97021.ab
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC1895202/
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC125246/
  34. https://pmc.ncbi.nlm.nih.gov/articles/PMC1303709/
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC3369959/
  36. https://www.ahajournals.org/doi/10.1161/atvbaha.107.150474
  37. https://www.ahajournals.org/doi/10.1161/atvbaha.110.207522
  38. https://www.ahajournals.org/doi/10.1161/01.res.0000251742.71301.16
  39. https://www.nature.com/articles/s41392-025-02198-8
  40. https://ashpublications.org/blood/article/146/12/1400/535292/Platelet-activation-and-signaling-in-thrombus
  41. https://physoc.onlinelibrary.wiley.com/doi/full/10.1113/expphysiol.2007.038588
  42. https://pmc.ncbi.nlm.nih.gov/articles/PMC1297263/
  43. https://pmc.ncbi.nlm.nih.gov/articles/PMC6407232/
  44. https://www.ncbi.nlm.nih.gov/books/NBK539817/
  45. https://pmc.ncbi.nlm.nih.gov/articles/PMC1868805/
  46. https://pmc.ncbi.nlm.nih.gov/articles/PMC9410115/
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC3056595/
  48. https://www.ncbi.nlm.nih.gov/books/NBK534253/
  49. https://pmc.ncbi.nlm.nih.gov/articles/PMC8051825/
  50. https://ashpublications.org/blood/article/132/13/1360/105710/Neutrophils-NETs-and-immunothrombosis
  51. https://journals.lww.com/hemasphere/fulltext/2019/06002/platelet_neutrophil_crosstalk_and_netosis.35.aspx
  52. https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.314645
  53. https://link.springer.com/article/10.1007/s00018-009-0210-4
  54. https://jintensivecare.biomedcentral.com/articles/10.1186/s40560-019-0387-z
  55. https://www.mdpi.com/1422-0067/26/13/6114
  56. https://pmc.ncbi.nlm.nih.gov/articles/PMC7397646/
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC11956735/
  58. https://pmc.ncbi.nlm.nih.gov/articles/PMC10138547/
  59. https://pmc.ncbi.nlm.nih.gov/articles/PMC10225702/
  60. https://www.jci.org/articles/view/27196
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC4872052/
  62. https://pmc.ncbi.nlm.nih.gov/articles/PMC8947573/
  63. https://www.sciencedirect.com/science/article/pii/S1538783622175975
  64. https://pmc.ncbi.nlm.nih.gov/articles/PMC2744593/
  65. https://www.ahajournals.org/doi/10.1161/circresaha.110.223883
  66. https://pmc.ncbi.nlm.nih.gov/articles/PMC3392496/
  67. https://pmc.ncbi.nlm.nih.gov/articles/PMC5936789/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3073541/
  69. https://www.sciencedirect.com/science/article/pii/S0301472X07003517
  70. https://pmc.ncbi.nlm.nih.gov/articles/PMC8699996/
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC8863951/
  72. https://pmc.ncbi.nlm.nih.gov/articles/PMC9791329/
  73. https://pmc.ncbi.nlm.nih.gov/articles/PMC1573478/
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4664089/
  75. https://www.sciencedirect.com/science/article/pii/S0009898125003936
  76. https://journals.sagepub.com/doi/10.1177/1076029612458147
  77. https://my.clevelandclinic.org/health/diagnostics/23572-mpv-blood-test
  78. https://onlinelibrary.wiley.com/doi/10.1111/ijlh.13177
  79. https://journals.lww.com/md-journal/fulltext/2020/02140/immature_platelet_fraction__a_useful_marker_for.42.aspx
  80. https://pmc.ncbi.nlm.nih.gov/articles/PMC5164902/
  81. https://haematologica.org/article/view/12002
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC4340464/
  83. https://pmc.ncbi.nlm.nih.gov/articles/PMC3557001/
  84. https://www.ncbi.nlm.nih.gov/books/NBK537233/
  85. https://pubmed.ncbi.nlm.nih.gov/19660606/
  86. https://pmc.ncbi.nlm.nih.gov/articles/PMC8049919/
  87. https://pubmed.ncbi.nlm.nih.gov/39603778/
  88. https://pubmed.ncbi.nlm.nih.gov/10938890/
  89. https://pubmed.ncbi.nlm.nih.gov/10544909/
  90. https://pmc.ncbi.nlm.nih.gov/articles/PMC4568902/
  91. https://pubmed.ncbi.nlm.nih.gov/12812383/
  92. https://pmc.ncbi.nlm.nih.gov/articles/PMC7464122/
  93. https://www.stago.com/products-services/platelet-aggregation-line/
  94. https://pubmed.ncbi.nlm.nih.gov/19408189/
  95. https://www.tandfonline.com/doi/full/10.1080/09537104.2022.2156493
  96. https://diagnostics.roche.com/global/en/products/instruments/multiplate-5-analyzer-ins-3691.html
  97. https://pubmed.ncbi.nlm.nih.gov/19461090/
  98. https://www.jthjournal.org/article/S1538-7836%2822%2907053-2/fulltext
  99. https://pubmed.ncbi.nlm.nih.gov/20427204/
  100. https://www.sciencedirect.com/science/article/pii/S1538783622043562
  101. https://pmc.ncbi.nlm.nih.gov/articles/PMC4194382/
  102. https://www.tandfonline.com/doi/full/10.1080/09537104.2024.2427745
  103. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2024.1507972/full
  104. https://pubmed.ncbi.nlm.nih.gov/39737052/
  105. https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-022-00819-4
  106. https://www.ncbi.nlm.nih.gov/books/NBK542208/
  107. https://www.mayoclinic.org/diseases-conditions/thrombocytopenia/symptoms-causes/syc-20378293
  108. https://www.nhlbi.nih.gov/health/immune-thrombocytopenia
  109. https://pmc.ncbi.nlm.nih.gov/articles/PMC8478497/
  110. https://www.ncbi.nlm.nih.gov/books/NBK560810/
  111. https://www.nhlbi.nih.gov/health/thrombocythemia-thrombocytosis
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC3200282/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC7780200/
  114. https://www.ncbi.nlm.nih.gov/books/NBK539709/
  115. https://ashpublications.org/hematology/article/2007/1/363/19181/Thrombocytosis-and-Thrombosis
  116. https://pubmed.ncbi.nlm.nih.gov/8951772/
  117. https://pubmed.ncbi.nlm.nih.gov/38269572/
  118. https://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/acquired-platelet-dysfunction
  119. https://www.ncbi.nlm.nih.gov/books/NBK557671/
  120. https://pmc.ncbi.nlm.nih.gov/articles/PMC4501245/
  121. https://www.ncbi.nlm.nih.gov/books/NBK537062/
  122. https://pmc.ncbi.nlm.nih.gov/articles/PMC4952969/
  123. https://www.ahajournals.org/doi/10.1161/CIR.0000000000001309
  124. https://www.ahajournals.org/doi/10.1161/circinterventions.111.966176
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC10109212/
  126. https://pmc.ncbi.nlm.nih.gov/articles/PMC6206448/
  127. https://pmc.ncbi.nlm.nih.gov/articles/PMC8832164/
  128. https://pmc.ncbi.nlm.nih.gov/articles/PMC3417919/
  129. https://pmc.ncbi.nlm.nih.gov/articles/PMC9896394/
  130. https://pmc.ncbi.nlm.nih.gov/articles/PMC3278069/
  131. https://pmc.ncbi.nlm.nih.gov/articles/PMC11289862/
  132. https://pmc.ncbi.nlm.nih.gov/articles/PMC2683811/
  133. https://pmc.ncbi.nlm.nih.gov/articles/PMC7505620/
  134. https://www.nejm.org/doi/full/10.1056/NEJMoa2109965
  135. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avatrombopag-chronic-immune-thrombocytopenia
  136. https://haematologica.org/article/view/8925
  137. https://pubmed.ncbi.nlm.nih.gov/25383671/
  138. https://www.ncbi.nlm.nih.gov/books/NBK560632/
  139. https://ashpublications.org/hematology/article/2020/1/527/474305/Platelet-transfusion-refractoriness-how-do-I
  140. https://pubmed.ncbi.nlm.nih.gov/31602653/
  141. https://pubmed.ncbi.nlm.nih.gov/37027143/
  142. https://www.aabb.org/news-resources/news/article/2024/08/28/novel-ex-vivo-platelet-additive-could-extend-cold-storage-to-14-days
  143. https://pubmed.ncbi.nlm.nih.gov/40459210/
  144. https://pmc.ncbi.nlm.nih.gov/articles/PMC2798780/
  145. https://pmc.ncbi.nlm.nih.gov/articles/PMC7427034/
  146. https://pmc.ncbi.nlm.nih.gov/articles/PMC6572609/
  147. https://www.dovepress.com/platelet-rich-plasma-for-the-treatment-of-chronic-wounds-evidence-to-d-peer-reviewed-fulltext-article-CWCMR
  148. https://link.springer.com/content/pdf/10.1007/978-1-4684-0820-1.pdf
  149. https://pubmed.ncbi.nlm.nih.gov/17383722/
  150. https://jamanetwork.com/journals/jama/fullarticle/183996
  151. https://www.jthjournal.org/article/S1538-7836(22)16026-5/fulltext
  152. https://ashpublications.org/blood/article/112/8/3011/114935/The-GPIIb-IIIa-integrin-IIb-3-odyssey-a-technology
  153. https://pmc.ncbi.nlm.nih.gov/articles/PMC10099789/
  154. https://pubmed.ncbi.nlm.nih.gov/24528208/
  155. https://ashpublications.org/blood/article/117/7/2102/28211/The-platelet-P2Y12-receptor-for-adenosine
  156. https://pmc.ncbi.nlm.nih.gov/articles/PMC11404911/
  157. https://www.sciencedirect.com/science/article/abs/pii/S0165247814002648
  158. https://www.vetlexicon.com/exotis/reptiles/laboratory-medicine/articles/hematology-platelet-count/
  159. https://onlinelibrary.wiley.com/doi/10.1002/9781118993705.ch3
  160. https://pmc.ncbi.nlm.nih.gov/articles/PMC10454457/
  161. https://www.harrisonsbirdfoods.com/wp-content/uploads/2024/03/176-198-Ch9-Hematology.pdf
  162. https://www.researchgate.net/figure/Avian-thrombocytes-express-genes-associated-with-platelet-function-and-signal-in-response_fig1_51547424
  163. https://www.sciencedirect.com/science/article/pii/S1050464824001530
  164. https://dergipark.org.tr/tr/download/article-file/57466
  165. https://pmc.ncbi.nlm.nih.gov/articles/PMC11293624/
  166. https://seer.ufrgs.br/rbrasbioci/article/download/114868/62145/475286
  167. https://journals.physiology.org/doi/full/10.1152/ajpregu.1999.276.3.R659
  168. https://www.alice.cnptia.embrapa.br/alice/bitstream/doc/349603/1/CPAFAP2009reviewblood.pdf
  169. https://www.sciencedirect.com/science/article/pii/S0044848621011613
  170. https://pmc.ncbi.nlm.nih.gov/articles/PMC11115950/
  171. https://www.sciencedirect.com/science/article/pii/S0965174818304417
  172. https://www.nature.com/articles/s41598-019-40129-0
  173. https://www.mdpi.com/2075-4450/11/1/62
  174. https://onlinelibrary.wiley.com/doi/10.1111/imm.13390
  175. https://pmc.ncbi.nlm.nih.gov/articles/PMC10112974/
  176. https://pubmed.ncbi.nlm.nih.gov/36515566/
  177. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0052622
  178. https://link.springer.com/article/10.1007/s10555-022-10019-5
Add your contribution
Related Hubs
User Avatar
No comments yet.